Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Zamicastat on Treprostinil PK in Healthy Subjects
NCT04675944Phase 1Completed
- Sponsor
- BIAL
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration at 72 hours, Area under the plasma concentration-time curve from time zero to the last quantifiable concentration and 3 more. Started Feb 2018; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04675944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675944.